Effectiveness and Safety of Guselkumab in Patients With Moderate‐to‐Severe Plaque Psoriasis in Real‐World Practice in Korea: A Prospective, Multicenter, Observational, Postmarketing Surveillance Study
The Journal of Dermatology · 2025
DOI: 10.1111/1346-8138.17757 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Bong Seok Shin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Chosun University College of Medicine, Gwangju, Republic of Korea. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Korea Ltd.
Abstract (Originalsprache)
Clinical trials have demonstrated the efficacy and safety of guselkumab in patients with moderate‐to‐severe plaque psoriasis. Real‐world evidence for guselkumab in Korea is needed to establish drug safety and effectiveness under real‐world practice in this population. This study assessed the effectiveness, safety, and drug survival of guselkumab in Korean patients with moderate‐to‐severe plaque psoriasis in a real‐world clinical setting. In this prospective, non‐interventional observational study conducted at 44 clinical centers in South Korea, adult patients with moderate‐to‐severe plaque psoriasis who would receive guselkumab per the product label were enrolled. Disease assessment was performed at visits 1 (baseline, week 0), 2 (approximately week 4), and 3–7 (approximately every 8 weeks after week 4, weeks 12–44). Between February 25, 2019 and March 25, 2022, 707 patients were enrolled and 562 (79.5%) had completed the 56‐week observation period. The proportions of patients with an absolute Psoriasis Area and Severity Index (PASI) score of ≤ 3, ≤ 2, or ≤ 1 reached maximums of 96.0%, 86.7%, and 59.0%, respectively, at visit 7. A significantly greater proportion of biologic‐naïve (vs. biologic‐experienced) patients achieved absolute PASI ≤ 3 by visits 5–7 ( p = 0.001 at visit 7) and absolute PASI ≤ 2 by visits 6–7 ( p = 0.0014 at visit 7). Dermatology Life Quality Index (DLQI) scores decreased over time, with 64.1% of patients achieving DLQI 0/1 by visit 7; results were similar regardless of prior biologic therapy. The estimated drug‐survival rate at 1 year was 92.7%. Adverse events (AEs) occurred in 22.5% of patients, with an incidence rate of 42.1 per 100 patient years (PY); 14 serious AEs occurred in 13 (1.8%) patients, with an incidence rate (95% confidence interval) of 2.4 (1.2–3.7) per 100 PY. Guselkumab administered under approved label conditions was effective and well‐tolerated in Korean patients with moderate‐to‐severe plaque psoriasis in a real‐world clinical setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Chosun University College of Medicine, Gwangju, Republic of Korea.
- Department of Dermatology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Dermatology, Dongguk University College of Medicine, Gyeongju, Republic of Korea.
- Department of Dermatology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, Republic of Korea.
- Department of Dermatology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
- Department of Dermatology, College of Medicine, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea.
ORCID-Profile: Miri Kim, Sang Woong Youn, Jihye An
Förderung
- Janssen Korea Ltd
Zitieren
APA
Shin, B. S., Kim, M., Suh, M. K., Lee, Y. B., Youn, S. W., Lee, J. Y., Kim, C. W., Lee, G. Y., Son, S. W., Kim, K. H., An, J., Kim, Y., Kim, K. J., & Kim, D. H. (2025). Effectiveness and Safety of Guselkumab in Patients With Moderate‐to‐Severe Plaque Psoriasis in Real‐World Practice in Korea: A Prospective, Multicenter, Observational, Postmarketing Surveillance Study. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17757
Vancouver
Shin BS, Kim M, Suh MK, Lee YB, Youn SW, Lee JY, et al. Effectiveness and Safety of Guselkumab in Patients With Moderate‐to‐Severe Plaque Psoriasis in Real‐World Practice in Korea: A Prospective, Multicenter, Observational, Postmarketing Surveillance Study. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17757
BibTeX
@article{Shin2025,
author = {Shin, Bong Seok and Kim, Miri and Suh, Moo Kyu and Lee, Young Bok and Youn, Sang Woong and Lee, Ji Yeoun and Kim, Chul Woo and Lee, Ga-Young and Son, Sang Wook and Kim, Kwang Ho and An, Jihye and Kim, Youngdoe and Kim, Kwang Joong and Kim, Dong Hyun},
title = {Effectiveness and Safety of Guselkumab in Patients With Moderate‐to‐Severe Plaque Psoriasis in Real‐World Practice in Korea: A Prospective, Multicenter, Observational, Postmarketing Surveillance Study},
journal = {The Journal of Dermatology},
year = {2025},
doi = {10.1111/1346-8138.17757}
}
EUVIMED